FCGR2C and breast cancer: Although the anti-cancer activity of CD32-CR T cells is preferentially directed towards BC cells, we have also evidence that some CRC and glioblastoma cell lines can be targeted (data not shown), whereas most hematopoietic malignant cells, we have used, are resistant (Marei et al, 2019).